<DOC>
	<DOCNO>NCT01233635</DOCNO>
	<brief_summary>In present application , propose refine extend current insight AAF mechanism therapy examine importance pharmacologic RAAS inhibition , ACE genotype , interaction secondary AF prevention . We 3 specific aim : 1 . To confirm RAAS inhibition therapy reduce incidence AF recurrence . 2 . To test hypothesis incidence AF recurrence absence RAAS inhibition therapy high among patient D allele . 3 . To explore hypothesis RAAS inhibition therapy effective preventing AF recurrence patient DD genotype DI II genotype .</brief_summary>
	<brief_title>Secondary Prevention Atrial Fibrillation ( Impact Renin-Angiotensin-Aldosterone System Inhibition )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Subjects must atrial fibrillation confirm 12 lead EKG . blood pressure &gt; 90 mmHg Patient without cardiopulmonary symptom 18+ year age Contraindiction warfarin Recent ( within 6 month ) MI cardiac revascularization Recent ( within 6 month ) CVA TIA NYHA Class IV CHF Active thyroid disease Major hepatic dysfunction Renal dysfunction ( &gt; 2 mg/dL ) Hyperkalemia ( &gt; 4.6 mEq/L ) Hyponatremia ( &lt; 130 mEq/L ) Currently take VaughnWilliams Type I III antiarrhythmic drug History ARB intolerance Contraindication ARB therapy Pregnancy Female childbearing age Age &lt; 18 year age Inability give inform consent Other medical condition call 1 year survival question</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>